治疗哮喘的前列腺素D2受体拮抗药fevipiprant的研究进展

Research Advance in Fevipiprant as a Prostaglandin D2 Acceptor Antagonist in the Treatment of Asthma

Fevipiprant具有全新抗哮喘的作用机制,是首个前列腺素D2受体抑制药,用于口服治疗嗜酸性粒细胞哮喘患者,可改善肺功能和削减嗜酸粒细胞炎症,安全性和耐受性较好,有良好的临床应用前景。

Fevipiprant with a novel mechanism for anti-asthma is the first prostaglandin D2 receptor inhibitor.It is orally administered in the treatment of patients with severe eosinophilic phenotype.It has also demonstrated with acceptable safety and tolerability in clinical studies as evidences of significant reduction of eosinophilic inflammation and effective improvement of pulmonary function, which displays good prospect for its clinical application.